. | Stage 1 N = 0 (0%) . | Stage 2 N = 27 (15.7%) . | Stage 3 N = 80 (46.5%) . | Stage 4 N = 62 (36%) . | Stage 5 N = 3 (1.7%) . | P-value . |
---|---|---|---|---|---|---|
AKI | 1 (3.7%) | 8 (10%) | 27 (44%) | 3 (100%) | <0.001 | |
Shock-LCOS | 4 (15%) | 40 (50%) | 44 (71%) | 3 (100%) | <0.001 | |
New PM | 2 (7.4%) | 8 (10%) | 8 (13%) | 0 (0%) | 0.853 | |
Death | 0 (0%) | 0 (0%) | 10 (16.1%) | 0 (0%) | <0.001 |
. | Stage 1 N = 0 (0%) . | Stage 2 N = 27 (15.7%) . | Stage 3 N = 80 (46.5%) . | Stage 4 N = 62 (36%) . | Stage 5 N = 3 (1.7%) . | P-value . |
---|---|---|---|---|---|---|
AKI | 1 (3.7%) | 8 (10%) | 27 (44%) | 3 (100%) | <0.001 | |
Shock-LCOS | 4 (15%) | 40 (50%) | 44 (71%) | 3 (100%) | <0.001 | |
New PM | 2 (7.4%) | 8 (10%) | 8 (13%) | 0 (0%) | 0.853 | |
Death | 0 (0%) | 0 (0%) | 10 (16.1%) | 0 (0%) | <0.001 |
AKI: acute kidney injury; LCOS: low cardiac output syndrome; PM: pacemaker.
. | Stage 1 N = 0 (0%) . | Stage 2 N = 27 (15.7%) . | Stage 3 N = 80 (46.5%) . | Stage 4 N = 62 (36%) . | Stage 5 N = 3 (1.7%) . | P-value . |
---|---|---|---|---|---|---|
AKI | 1 (3.7%) | 8 (10%) | 27 (44%) | 3 (100%) | <0.001 | |
Shock-LCOS | 4 (15%) | 40 (50%) | 44 (71%) | 3 (100%) | <0.001 | |
New PM | 2 (7.4%) | 8 (10%) | 8 (13%) | 0 (0%) | 0.853 | |
Death | 0 (0%) | 0 (0%) | 10 (16.1%) | 0 (0%) | <0.001 |
. | Stage 1 N = 0 (0%) . | Stage 2 N = 27 (15.7%) . | Stage 3 N = 80 (46.5%) . | Stage 4 N = 62 (36%) . | Stage 5 N = 3 (1.7%) . | P-value . |
---|---|---|---|---|---|---|
AKI | 1 (3.7%) | 8 (10%) | 27 (44%) | 3 (100%) | <0.001 | |
Shock-LCOS | 4 (15%) | 40 (50%) | 44 (71%) | 3 (100%) | <0.001 | |
New PM | 2 (7.4%) | 8 (10%) | 8 (13%) | 0 (0%) | 0.853 | |
Death | 0 (0%) | 0 (0%) | 10 (16.1%) | 0 (0%) | <0.001 |
AKI: acute kidney injury; LCOS: low cardiac output syndrome; PM: pacemaker.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.